Editor’s Choice: Notable Pink Sheet Articles From Q3
A must-read selection of intriguing and popular articles posted in the Pink Sheet over the past three months.
You may also be interested in...
Coverage of clinical trial policy included commentary on rapid growth of the PD-1 pipeline by both US and China regulators; case studies and discussion of trial strategies including RWE, pediatric studies and decentralized trials; and US FDA commissioner-nominee Robert Califf’s R&D expertise.
Please take our brief reader survey to help us better understand your content and delivery needs.
Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.